 | | Venous thromboembolism: The past and the present |
|  | | Outline |
|
 | | The Past I |
|  | | The Past II |
|
 | | The Past III |
|  | | Classes of new anticoagulants |
|
 | | Treatment Data Available |
|  | | Biotinylated idraparinux : Structure and product profile |
|
 | | Equinox |
|  | | EQUINOX VTE recurrences at 6 months |
|
 | | EQUINOX Safety data at 6 months |
|  | | Study Design |
|
 | | Primary efficacy outcome analysis |
|  | | Efficacy results |
|
 | | Primary safety outcome analysis |
|  | | Bleeding results |
|
 | | Idrabiotaprinux is a good and attractive alternative for VKA in the treatment of DVT and PE |
|  | | Dabigatran Etexilate |
|
 | | Recover I |
|  | | Recover I VTE recurrences at 6 months |
|
 | | Recover I Safety data at 6 months |
|  | | Resonate |
|
 | | Resonate |
|  | | Still to come |
|
 | | Human Factor Xa/rivaroxaban complex |
|  | | EINSTEIN: study designs |
|
 | | EINSTEIN DVT: primary efficacy outcome |
|  | | EINSTEIN DVT: principal safety outcome analysis |
|
 | | Still to come |
|  | | Others joining soon |
|
 | | Conclusions |
|  | | Future |
|
 | | Influence of statin therapy on recurrent pulmonary embolism |
|  | | Future |
|
Deel deze pagina met collega's en vrienden: